


Prior Authorization Review Panel

CHIP-MCO Policy Submission

A separate copy of this form must accompany each policy submitted for review.
Policies submitted without this form will not be considered for review.

Plan: PA Health & Wellness	Submission Date: 02/01/2026
Policy Number: PA.CHIP.PHAR.124	Effective Date: 01/2026 Revision Date: 01/2026
Policy Name: Alirocumab (Praluent)	
Type of Submission – <u>Check all that apply:</u> <input type="checkbox"/> New Policy <input checked="" type="checkbox"/> Revised Policy* <input type="checkbox"/> Annual Review - No Revisions <input type="checkbox"/> Statewide PDL - <i>Select this box when submitting policies for Statewide PDL implementation and when submitting policies for drug classes included on the Statewide PDL.</i>	
*All revisions to the policy <u>must</u> be highlighted using track changes throughout the document. Please provide any changes or clarifying information for the policy below: 1Q 2026 annual review: for all indications, extended initial approval duration to 12 months for this maintenance medication for a chronic condition; removed pediatric use in HoFH per PI; references reviewed and updated. RT4: updated indication to reflect the following revised uses: as an adjunct to exercise (rather than LDL-lowering therapy) for HeFH and HoFH and to reduce major adverse CV events in adults at increased risk for these events (rather than adults with established CV disease) per PI; revised “hyperlipidemia” to “hypercholesterolemia” throughout the criteria.	
Name of Authorized Individual (Please type or print): Craig A. Butler, MD MBA	Signature of Authorized Individual: 

Clinical Policy: Alirocumab (Praluent)

Reference Number: PA.CHIP.PHAR.124

Effective Date: 01/2026

Last Review Date: 01/2026

Description

Alirocumab (Praluent[®]) is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor antibody.

FDA Approved Indication(s)

Praluent is indicated:

- To reduce the risk of major adverse cardiovascular (CV) events (coronary heart disease death, myocardial infarction, stroke, or unstable angina requiring hospitalization) in adults at increased risk for these events
- As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in:
 - adults with hypercholesterolemia
 - adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH)
 - adults with homozygous familial hypercholesterolemia (HoFH)

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of PA Health & Wellness[®] that Praluent is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Primary Hypercholesterolemia (including HeFH) and Cardiovascular Event Risk Reduction (must meet all):

1. Diagnosis of one of the following (a, b, or c):
 - a. **HeFH**, and provider's attestation of both of the following (i and ii):
 - i. Baseline LDL-C (prior to any lipid-lowering pharmacologic therapy) was one of the following (1 or 2): 1)
 1. If age < 20 years: ≥ 160 mg/dL;
 2. If age ≥ 20 years: ≥ 190 mg/dL;
 - ii. HeFH diagnosis is confirmed by one of the following (1 or 2):
 1. World Health Organization (WHO)/Dutch Lipid Network familial hypercholesterolemia diagnostic criteria score of > 8 as determined by requesting provider (see Appendix D);
 2. Definite diagnosis per Simon Broome criteria (see Appendix D);
 - b. **Primary hypercholesterolemia that is not HeFH**, and both of the following (i and ii):
 - i. Provider's attestation of one of the following (1 or 2):
 1. Presence of a genetically mediated form of primary hypercholesterolemia as evidenced by confirmatory genetic testing results;
 2. A diagnosis of secondary hypercholesterolemia has been ruled out with absence of all of the following potential causes of elevated cholesterol (a – e):
 - a. Poor diet;
 - b. Hypothyroidism;
 - c. Obstructive liver disease;

- d. Renal disease;
 - e. Nephrosis;
 - ii. Provider's attestation that baseline LDL-C (prior to any lipid-lowering pharmacologic therapy) was ≥ 190 mg/dL;
 - c. **Increased risk for CV events** as evidenced by provider's attestation of a history of **atherosclerotic cardiovascular disease (ASCVD)** including of any one of the following conditions (i-vii):
 - i. Acute coronary syndromes;
 - ii. Clinically significant coronary heart disease (CHD) diagnosed by invasive or noninvasive testing (such as coronary angiography, stress test using treadmill, stress echocardiography, or nuclear imaging);
 - iii. Coronary or other arterial revascularization;
 - iv. Myocardial infarction;
 - v. Peripheral arterial disease presumed to be of atherosclerotic origin;
 - vi. Stable or unstable angina;
 - vii. Stroke or transient ischemic attack (TIA);
2. Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist;
 3. Age is one of the following (a or b):
 - a. If diagnosis is primary hypercholesterolemia (not including HeFH) or ASCVD: ≥ 18 years;
 - b. If diagnosis is HeFH: ≥ 8 years;
 4. For members ≥ 18 years old on statin therapy, both of the following (a and b):
 - a. Praluent is prescribed in conjunction with a statin at the maximally tolerated dose;
 - b. Member has been adherent for at least the last 8 weeks to maximally tolerated doses of one of the following statin regimens (i or ii):
 - i. A high intensity statin (*see Appendix E*);
 - ii. A moderate or low intensity statin (*see Appendix E*), and member has one of the following (1 or 2):
 1. Previous use of one high-intensity statin (i.e., atorvastatin ≥ 40 mg daily; rosuvastatin ≥ 20 mg daily [as a single-entity or as a combination product]) for a minimum of 8 weeks continuously and LDL-C remained ≥ 70 mg/dL;
 2. Member has tried both rosuvastatin and atorvastatin and has experienced skeletal-muscle related symptoms on both agents which also resolved upon discontinuation;
 5. For members ≥ 18 years old not on statin therapy, provider's attestation that member meets one of the following (a or b):
 - a. Statin therapy is contraindicated per Appendix F;
 - b. For members who are statin intolerant, both of the following (i and ii):
 - i. Member has tried at least two statins, one of which must be hydrophilic (pravastatin, fluvastatin, or rosuvastatin);
 - ii. Member meets one of the following (1 or 2):
 1. Member has statin risk factors (*see Appendix G*);
 2. Member is statin intolerant due to statin-associated muscle symptoms (SAMS) and meets both of the following (a and b):
 - a. Member had intolerable SAMS persisting at least two weeks, which disappeared with discontinuing the statin therapy and recurred with a statin re-challenge;
 - b. Previous re-challenge with titration from lowest possible dose and/or intermittent dosing frequency (e.g., 1 to 3 times weekly);
 6. Provider's attestation of recent (within the last 60 days) LDL-C of one of the following (a or b):

- a. If member has ASCVD (i or ii):
 - i. ≥ 70 mg/dL;
 - ii. ≥ 55 mg/dL, and member is at very high risk (see *Appendix I*);
- b. If member has severe primary hypercholesterolemia (including HeFH): ≥ 100 mg/dL;
- 7. Treatment plan does not include coadministration with Juxtapid[®], Leqvio[®], or Repatha[®];
- 8. Dose does not exceed one of the following (a, b, or c):
 - a. Age ≥ 18 years: 75 mg every 2 weeks or 300 mg per month;
 - b. Age ≥ 8 years to < 18 years and weight ≥ 50 kg: 300 mg every 4 weeks;
 - c. Age ≥ 8 years to < 18 years and weight < 50 kg: 150 mg every 4 weeks.

Approval duration: 12 months

B. Homozygous Familial Hypercholesterolemia (must meet all):

- 1. Diagnosis of HoFH;
- 2. Provider's attestation defined as one of the following (a, b, or c):
 - a. Genetic mutation indicating HoFH (e.g., mutations in low density lipoprotein receptor [LDLR] gene, PCSK9 gene, apo B gene, low density lipoprotein receptor adaptor protein 1 [LDLRAP1] gene);
 - b. Treated LDL-C ≥ 300 mg/dL or non-HDL-C ≥ 330 mg/dL;
 - c. Untreated LDL-C ≥ 400 mg/dL, and one of the following (i or ii):
 - i. Tendinous or cutaneous xanthoma prior to age 10 years;
 - ii. Evidence of familial hypercholesterolemia (HeFH or HoFH) in at least one parent (e.g., documented history of elevated LDL-C ≥ 190 mg/dL prior to lipid-lowering therapy);
- 3. Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist;
- 4. Age ≥ 18 years, and provider's attestation of recent (within the last 60 days) LDL-C of one of the following (a or b):
 - a. ≥ 70 mg/dL;
 - b. ≥ 55 mg/dL if member has ASCVD and is at very high risk (see *Appendix I*);
- 5. For members on statin therapy, provider's attestation of both of the following (a and b):
 - a. Praluent is prescribed in conjunction with a statin at the maximally tolerated dose;
 - b. Member has been adherent for at least the last 8 weeks to maximally tolerated doses of one of the following statin regimens (i or ii):
 - i. A high intensity statin (see *Appendix E*);
 - ii. A moderate or low intensity statin (see *Appendix E*) and member has one of the following (1 or 2):
 - 1. Previous use of one high-intensity statin (i.e., atorvastatin ≥ 40 mg daily; rosuvastatin ≥ 20 mg daily [as a single-entity or as a combination product]) for a minimum of 8 weeks continuously and LDL-C remained ≥ 70 mg/dL;
 - 2. Member has tried both rosuvastatin and atorvastatin and has experienced skeletal-muscle related symptoms on both agents which also resolved upon discontinuation;
- 6. For members not on statin therapy, provider's attestation that member meets one of the following (a or b):
 - a. Statin therapy is contraindicated per *Appendix F*;
 - b. For members who are statin intolerant, both of the following (i and ii):
 - i. Member has tried at least two statins, one of which must be hydrophilic (pravastatin, fluvastatin, or rosuvastatin);
 - ii. Member meets one of the following (1 or 2):
 - 1. Member has statin risk factors (see *Appendix G*);

2. Member is statin intolerant due to statin-associated muscle symptoms (SAMS) and meets both of the following (a and b):
 - a. Member had intolerable SAMS persisting at least two weeks, which disappeared with discontinuing the statin therapy and recurred with a statin re-challenge;
 - b. Previous re-challenge with titration from lowest possible dose and/or intermittent dosing frequency (e.g., 1 to 3 times weekly);
6. For members ≥ 18 years old and not on statin therapy, provider's attestation that member meets one of the following (a or b):
 - a. Statin therapy is contraindicated per Appendix F;
 - b. For members who are statin intolerant, both of the following (i and ii):
 - i. Member has tried at least two statins, one of which must be hydrophilic (pravastatin, fluvastatin, or rosuvastatin);
 - ii. Member meets one of the following (1 or 2):
 1. Member has statin risk factors (see Appendix G);
 2. Member is statin intolerant due to statin-associated muscle symptoms (SAMS) and meets both of the following (a and b):
 - a. Member had intolerable SAMS persisting at least two weeks, which disappeared with discontinuing the statin therapy and recurred with a statin re-challenge;
 - b. Previous re-challenge with titration from lowest possible dose and/or intermittent dosing frequency (e.g., 1 to 3 times weekly);
 7. Treatment plan does not include coadministration with Leqvio, Juxtapid or Repatha;
 8. Dose does not exceed 150 mg every 2 weeks.

Approval duration: 6 months or to the member's renewal date

C. Other diagnoses/indications

1. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53

II. Continued Therapy

A. Primary Hyperlipidemia (including HeFH) and Atherosclerotic Cardiovascular Disease (must meet all):

1. Currently receiving medication via PA Health & Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.PHARM.01) applies;
2. If statin tolerant, provider's attestation of adherence to a statin at the maximally tolerated dose;
3. Treatment plan does not include coadministration with Leqvio, Juxtapid or Repatha;
4. Member meets one of the following (a or b):
 - a. For age ≥ 18 years, one of the following (i or ii):
 - i. Request is for 75 mg every 2 weeks or 300 mg every month, and provider's attestation of lab results within the last 3 months are submitted showing an LDL-C reduction since initiation of Praluent therapy;
 - ii. Request is for 150 mg every 2 weeks, and one of the following (1 or 2):
 1. If request represents a new dose increase, member meets both (a and b):
 - a. Provider's attestation of adherence to Praluent and, if applicable, statin therapies;
 - b. Provider's attestation of lab results within the last 3 months are submitted showing an LDL-C > 70 mg/dL after a minimum of 8 weeks of Praluent therapy at 75 mg;
 2. If request represents a continuation of Praluent 150 mg, provider's attestation of lab results within the last 3 months are submitted showing an LDL-C

- reduction since initiation of the Praluent dose increase;
- b. For age ≥ 8 years to < 18 years, one of the following (i or ii):
 - i. For body weight ≥ 50 kg, one of the following (1 or 2):
 - 1. Request is for 300 mg every month, and provider's attestation of lab results within the last 3 months are submitted showing an LDL-C reduction since initiation of Praluent therapy;
 - 2. Request is for 150 mg every 2 weeks, and one of the following (a or b):
 - a. If request represents a new dose increase, member meets both (i and ii):
 - i. Provider's attestation of adherence to Praluent and, if applicable, statin therapies;
 - ii. Lab results within the last 3 months are submitted showing an LDL-C ≥ 110 mg/dL after a minimum of 8 weeks of Praluent therapy at 300 mg every month;
 - b. If request represents a continuation of Praluent 150 mg every 2 weeks, lab results within the last 3 months are submitted showing an LDL-C reduction since initiation of the Praluent frequency increase;
 - ii. For body weight < 50 kg, one of the following (1 or 2):
 - 1. Request is for 150 mg every 4 weeks, and provider's attestation of lab results within the last 3 months are submitted showing an LDL-C reduction since initiation of Praluent therapy;
 - 2. Request is for 75 mg every 2 weeks, and one of the following (a or b):
 - a. If request represents a new dose increase, member meets both (i and ii):
 - i. Provider's attestation of adherence to Praluent and, if applicable, statin therapies;
 - ii. Provider's attestation of lab results within the last 3 months are submitted showing an LDL-C ≥ 110 mg/dL after a minimum of 8 weeks of Praluent therapy at 150 mg every 4 weeks;
 - b. If request represents a continuation of Praluent 75 mg every 2 weeks, provider's attestation of lab results within the last 3 months are submitted showing an LDL-C reduction since initiation of the Praluent frequency increase.

Approval duration: 6 months

B. Primary Hyperlipidemia (including HeFH) and Atherosclerotic Cardiovascular Disease (must meet all):

1. Currently receiving medication via PA Health & Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.PHARM.01) applies;
2. If statin tolerant, provider's attestation of adherence to a statin at the maximally tolerated dose;
3. Member is responding positively to therapy as evidenced by provider's attestation of lab results within the last 3 months showing an LDL-C reduction since initiation of Praluent therapy;
4. Treatment plan does not include coadministration with Juxtapid, Leqvio, or Repatha;
5. If request is for a dose increase, new dose does not exceed 150 mg every 2 weeks.

Approval duration: 6 months

C. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via PA Health & Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.PHARM.01) applies.
Approval duration: Duration of request or 12 months (whichever is less); or
2. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.PMN.53

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

ALT: alanine transaminase	LDL-C: low density lipoprotein cholesterol
apo B: apolipoprotein B	LDLR: low density lipoprotein receptor
ASCVD: atherosclerotic cardiovascular disease	PCSK9: proprotein convertase subtilisin
CHD: coronary heart disease	SAMS: statin-associated muscle symptoms
FDA: Food and Drug Administration	TIA: transient ischemic attack
FH: familial hypercholesterolemia	WHO: World Health Organization
HeFH: heterozygous familial hypercholesterolemia	
HoFH: homozygous familial hypercholesterolemia	

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
atorvastatin (Lipitor [®])	40 mg PO QD	80 mg/day
rosuvastatin (Crestor [®])	5 - 40 mg PO QD	40 mg/day
pravastatin (Pravachol [®])	10 - 80 mg PO QD	80 mg/day
fluvastatin (Lescol [®])	20 - 80 mg PO QD	80 mg/day

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): history of serious hypersensitivity reaction to Praluent
- Boxed warning(s): none

Appendix D: Criteria for Diagnosis of HeFH

- Dutch Lipid Clinic Network criteria for Familial Hypercholesterolemia (FH)

FH Criteria	Points	Member's Score†
Family History		
First-degree relative with known premature* coronary and vascular disease	1	Place highest score here (0, 1 or 2)
First-degree relative with known LDL-C level above the 95 th percentile	1	
First-degree relative with tendinous xanthomata and/or arcus cornealis	2	
Children aged < 18 years with LDL-C level above the 95 th percentile	2	
Clinical History		
Patient with premature* coronary artery disease	2	Place highest score here (0, 1 or 2)
Patient with premature* cerebral or peripheral vascular disease	1	
Physical Examination		
Tendinous xanthomata	6	Place highest score here (0, 4 or 6)
Arcus cornealis prior to age 45 years	4	
Cholesterol Levels - mg/dL (mmol/liter)		
LDL-C ≥ 330 mg/dL (≥ 8.5)	8	Place highest score here (0, 1, 3, 5 or 8)
LDL-C 250 – 329 mg/dL (6.5 – 8.4)	5	
LDL-C 190 – 249 mg/dL (5.0 – 6.4)	3	
LDL-C 155 – 189 mg/dL (4.0 – 4.9)	1	
DNA Analysis		
Functional mutation in the <i>low density lipoprotein receptor (LDLR)</i> , <i>apo B</i> or <i>PCSK9</i> gene	8	Place highest score here (0 or 8)
TOTAL SCORE	Definite FH: > 8	Place score total here __

*Premature – men < 55 years or women < 60 years

†Choose the highest score from each of the five categories and then add together for a total score. The five categories are 1) Family History, 2) Clinical History, 3) Physical Examination, 4) Cholesterol Levels, and 5) DNA Analysis.

- Simon Broome Register Group Definition of Definite FH (meets 1 and 2):
 1. One of the following (a or b):
 - a. Total cholesterol level above 7.5 mmol/l (290 mg/dl) in adults or a total cholesterol level above 6.7 mmol/l (260 mg/dl) for children under 16;
 - b. LDL levels above 4.9 mmol/l (190 mg/dl) in adults (4.0 mmol/l in children) (either pre-treatment or highest on treatment);
 2. One of the following (a or b):
 - a. Tendinous xanthomas in patient or relative (parent, child, sibling, grandparent, aunt, uncle);
 - b. DNA-based evidence of an LDL receptor mutation or familial defective apo B- 100;
- High and Moderate Risk of ASCVD:
 - Patients with high risk of ASCVD include the following:
 - History of clinical atherosclerotic cardiovascular disease (as defined in section II)
 - Diabetes with an estimated 10-year ASCVD risk ≥ 7.5% for adults 40-75 years of age
 - Untreated LDL ≥ 190 mg/dL

- Patients with moderate risk of ASCVD include the following:
 - Diabetes with an estimated 10-year ASCVD risk < 7.5% for adults 40-75 years of age
 - Estimated 10-year ASCVD risk ≥ 5% for adults 40-75 years of age
- The calculator for the 10-year ASCVD risk estimator can be found here:
<http://tools.cardiosource.org/ASCVD-Risk-Estimator>. Information needed to complete the ASCVD Risk Estimator include: gender, race (white, African American, other), systolic blood pressure, diabetes, age, total cholesterol, HDL-Cholesterol, treatment for hypertension, current smoker.

Appendix E: High and Moderate Intensity Daily Statin Therapy for Adults

High Intensity Statin Therapy
<i>Daily dose shown to lower LDL-C, on average, by approximately ≥ 50%</i>
<ul style="list-style-type: none"> • Atorvastatin 40-80 mg • Rosuvastatin 20-40 mg
Moderate Intensity Statin Therapy
<i>Daily dose shown to lower LDL-C, on average, by approximately 30% to 50%</i>
<ul style="list-style-type: none"> • Atorvastatin 10-20 mg • Fluvastatin XL 80 mg • Fluvastatin 40 mg BID • Lovastatin 40 mg • Pitavastatin 1-4 mg • Pravastatin 40-80 mg • Rosuvastatin 5-10 mg • Simvastatin 20-40 mg
Low Intensity Statin Therapy
<i>Daily dose shown to lower LDL-C, on average, by < 30%</i>
<ul style="list-style-type: none"> • Simvastatin 10 mg • Pravastatin 10-20 mg • Lovastatin 20 mg • Fluvastatin 20-40 mg

Appendix F: Statin Contraindications

Statins
<ul style="list-style-type: none"> • Decompensated liver disease (development of jaundice, ascites, variceal bleeding, encephalopathy) • Laboratory-confirmed acute liver injury or rhabdomyolysis resulting from statin treatment • Pregnancy*, actively trying to become pregnant, or nursing • Immune-mediated hypersensitivity to the HMG-CoA reductase inhibitor drug class (statins) as evidenced by an allergic reaction occurring with at least TWO different statins

**In July 2021, the FDA requested removal of the contraindication against use of statins in pregnant women. Because the benefits of statins may include prevention of serious or potentially fatal events in a small group of very high-risk pregnant patients, contraindicating these drugs in all pregnant women is not appropriate. <https://www.fda.gov/safety/medical-product-safety-information/statins-drug-safety-communication-fda-requests-removal-strongest-warning-against-using-cholesterol>*

Appendix G: Statin Risk Factors

Statin Risk Factors

- Multiple or serious comorbidities, including impaired renal or hepatic function
- Unexplained alanine transaminase (ALT) elevations > 3 times upper limit of normal, or active liver disease
- Concomitant use of drugs adversely affecting statin metabolism
- Age > 75 years, or history of hemorrhagic stroke
- Asian ancestry

Appendix H: General Information

- FDA Endocrinologic and Metabolic Drugs Advisory Committee briefing documents for another PCSK-9 inhibitor, Praluent, discuss the questionable determination of statin intolerance, stating: “many patients who are not able to take statins are not truly intolerant of the pharmacological class.”
- Patients should remain on concomitant therapy with a statin if tolerated due to the established long term cardiovascular benefits.
- Examples of genetically mediated primary hypercholesterolemia include but are not limited to the following:
 - Familial hypercholesterolemia
 - Familial combined hyperlipidemia (FCHL)
 - Polygenic hypercholesterolemia
 - Familial dysbetalipoproteinemia
- The diagnosis of SAMS is often on the basis of clinical criteria. Typical SAMS include muscle pain and aching (myalgia), cramps, and weakness. Symptoms are usually bilateral and involve large muscle groups, including the thigh, buttock, back, and shoulder girdle musculature. In contrast, cramping is usually unilateral and may involve small muscles of the hands and feet. Symptoms may be more frequent in physically active patients. Symptoms often appear early after starting statin therapy or after an increase in dose and usually resolve or start to dissipate within weeks after cessation of therapy, although it may take several months for symptoms to totally resolve. Persistence of symptoms for more than 2 months after drug cessation should prompt a search for other causes or for underlying muscle disease possibly provoked by statin therapy. The reappearance of symptoms with statin rechallenge and their disappearance with drug cessation offers the best evidence that the symptoms are truly SAMS.
- Pravastatin, fluvastatin, and rosuvastatin are hydrophilic statins which have been reported to confer fewer adverse drug reactions than lipophilic statins.

Appendix I: Criteria for Defining Patients at Very High Risk of Future ASCVD Events² Very high risk is defined as having either a history of multiple major ASCVD events **OR** 1 major ASCVD event and multiple high-risk conditions:

- Major ASCVD events:
 - Recent acute coronary syndrome (within the past 12 months)
 - History of myocardial infarction (other than recent acute coronary syndrome event listed above)
 - History of ischemic stroke
 - Symptomatic peripheral artery disease (history of claudication with ankle-brachial index < 0.85 or previous revascularization or amputation)
- High-risk conditions:
 - Age ≥ 65 years
 - FH
 - History of prior coronary artery bypass surgery or percutaneous coronary intervention outside of the major ASCVD event(s)

- Diabetes
- Hypertension
- Chronic kidney disease (estimated glomerular filtration rate [eGFR] 15-59 mL/min/1.73 m²)
- Current tobacco smoking
- Persistently elevated LDL-C (LDL-C ≥ 100 mg/dL [≥ 2.6 mmol/L]) despite maximally tolerated statin therapy and ezetimibe
- History of congestive heart failure

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Hypercholesterolemia with increased risk for CV events	<p>75 mg SC once every 2 weeks or 300 mg SC once every 4 weeks</p> <p>If response to 75 mg every 2 weeks or 300 mg every 4 weeks is inadequate, dose may be adjusted to 150 mg once every 2 weeks</p>	300 mg/month
Primary hypercholesterolemia (including HeFH) (including HeFH)	<p><u>Adult:</u> 75 mg SC once every 2 weeks or 300 mg SC once every 4 weeks</p> <p>If response to 75 mg every 2 weeks or 300 mg every 4 weeks is inadequate, dose may be adjusted to 150 mg once every 2 weeks</p> <p><u>Pediatrics:</u> Body weight < 50 kg: 150 mg SC every 4 weeks If response is inadequate, dose may be adjusted to 75 mg every 2 weeks</p> <p>Body weight ≥ 50 kg: 300 mg SC every 4 weeks If response is inadequate, dose may be adjusted to 150 mg every 2 weeks</p> <p><u>Pediatrics:</u> Body weight < 50 kg: 150 mg SC every 4 weeks If response is inadequate, dose may be adjusted to 75 mg every 2 weeks</p> <p>Body weight ≥ 50 kg: 300 mg SC every 4 weeks If response is inadequate, dose may be adjusted to 150 mg every 2 weeks</p>	300 mg/month

HoFH, HeFH undergoing LDL apheresis	150 mg SC every 2 weeks	300 mg/month
---	-------------------------	--------------

VI. Product Availability

Single-use pre-filled pens: 75 mg/mL, 150 mg/mL

V. References

1. Praluent Prescribing Information. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; October 2025. Available at: https://www.regeneron.com/downloads/praluent_pi.pdf. Accessed October 21, 2025.
2. Blom DJ, Harada-Shiba M, Rubba P, et al. Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: The ODYSSEY HoFH trial. *J Am Coll Cardiol.* 2020; 76(2): 131-142.
Guidelines
3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2018;Nov 10:[Epub ahead of print].
4. Lloyd-Jones DM, Morris PB, Minissian MB, et al. 2017 Focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk. *J Am Coll Cardiol* 2017; 70(14):1785-1822. <http://dx.doi.org/10.1016/j.jacc.2017.07.745>.

5. Lloyd-Jones DM, Morris PB, Ballntyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2022; 80 (14): 1366-1418.
6. Jacobson TA, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 – full report. *Journal of Clinical Lipidology*. March-April 2015; 9(2): 129-169. <http://dx.doi.org/10.1016/j.jacl.2015.02.003>.
7. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *Journal of Clinical Lipidology*. June 2011; 5(3S): 1-15.
8. Al-Rasadi K, Al-Waili K, Al-Sabti HA, et al. Criteria for diagnosis of familial hypercholesterolemia: A comprehensive analysis of the different guidelines, appraising their suitability in the Omani Arab population. *Oman Medical Journal*. 2014; 29(2): 85–91. <http://doi.org/10.5001/omj.2014.22>.
9. Mach F, Baigent C, Catapano AL, et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455. Erratum in: *Eur Heart J*. 2020 Nov 21;41(44):4255. doi: 10.1093/eurheartj/ehz826.
10. Cuchel M, Raal FJ, Hegele RA, et al. 2023 Update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance. *Eur Heart J*. 2023 Jul 1;44(25):2277-2291. doi: 10.1093/eurheartj/ehad197.
11. Clinical Lipidology Resource Center, sponsored by the National Lipid Association and the *Journal of Clinical Lipidology*. Genetic classification of dyslipidemia. Available at: <http://nlaresourcecenter.lipidjournal.com/Content/PDFs/Tables/1.pdf>. Accessed October 21, 2025.
12. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association/American Stroke Association. *Stroke*. 2021; 52: e354-e467.
13. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines [published correction appears in *Circulation*. 2023 Sep 26;148(13):e148]. *Circulation*. 2023;148(9):e9-e119.
14. ElSayed NA, Aleppo G, Aroda VR, et al. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023 [published correction appears in *Diabetes Care*. 2023 Jan 26]. *Diabetes Care*. 2023;46(Suppl 1):S158-S190.
15. Jackson EJ, Willard KE, Ballantyne CM. LDL cholesterol management simplified in adults-Lower for longer is better: Guidance from the National Lipid Association. *J Clin Lipidol*. 2025 Jun 18:S1933-2874(25)00317-4. doi: 10.1016/j.jacl.2025.06.002.
Statin Tolerance
16. Fitchett DH, Hegele RA, Verma S. Statin intolerance. *Circulation* 2015;131:e389-391. <https://doi.org/10.1161/CIRCULATIONAHA.114.013189>
17. Food and Drug Administration Center for Drug Evaluation and Research: The Endocrinology and Metabolic Drugs Advisory Committee Meeting Briefing Document BLA 125559 – Praluent (alirocumab) injection. June 9, 2015. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125559Orig1s000ODMemo.pdf. Accessed October 21, 2025.
18. Manpuya WM, Cho L, Frid D, et al. Treatment strategies in patients with statin

intolerance: the Cleveland Clinic experience. *American Heart Journal* 2013; 166(3):597-603.

19. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings. *Ann of Intern Med* 2013; 158(7):526-534.
20. Backes JM, Ruisinger JF, Gibson CA, et al. Statin-associated muscle symptoms—managing the highly intolerant. *J Clin Lipidol.* 2017;11:24-33. Jan-Feb;11(1):24-33. doi: 10.1016/j.jacl.2017.01.006.
21. Thompson PD, Panza G, Zaleski A, et al. Statin-associated side effects. *J Am Coll Cardio* 2016 May 24;67(20):2395-2410. doi: 10.1016/j.jacc.2016.02.071.
22. Warden BA, Guyton JR, Kovacs AC, et al. Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association. *J Clin Lipidol.* 2023 Jan-Feb;17(1):19-39. doi: 10.1016/j.jacl.2022.09.001.
23. Cheeley MK, Saseen JJ, Agarwala A, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. *J Clin Lipidol.* 2022 Jul-Aug;16(4):361-375. doi: 10.1016/j.jacl.2022.05.068.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
C9399	Unclassified drugs or biologicals
J3590	Unclassified biologics

Reviews, Revisions, and Approvals	Date
Policy created	09/2025
1Q 2026 annual review: for all indications, extended initial approval duration to 12 months for this maintenance medication for a chronic condition; removed pediatric use in HoFH per PI; references reviewed and updated. RT4: updated indication to reflect the following revised uses: as an adjunct to exercise (rather than LDL-lowering therapy) for HeFH and HoFH and to reduce major adverse CV events in adults at increased risk for these events (rather than adults with established CV disease) per PI; revised “hyperlipidemia” to “hypercholesterolemia” throughout the criteria.	01/2026